OR WAIT null SECS
April 02, 2016
Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems.
March 02, 2016
Gauging the adequate level and type of screening is the challenge when identifying relevant crystalline forms.
Scale-down modeling accelerates the development of downstream biopharma manufacturing processes.
Hazardous reagents can prove to be faster, simpler, cheaper, and greener.
February 02, 2016
Scale-down modeling is instrumental in supporting the development of downstream biopharma manufacturing processes.
Hazardous reagents can simplify processes and provide higher yields and purities.
January 02, 2016
Nanoscale catalysts and engineered nanoparticles may have a big impact on small-molecule pharmaceuticals.
December 02, 2015
A strong API market is expected in 2016 despite fewer new drug approvals.
November 02, 2015
Efficient syntheses are possible using multi-component and cross-dehydrogenative, heteroaromatic C–H silylation reactions
Efficient syntheses are possible using multi-component and cross-dehydrogenative, heteroaromatic C-H silylation reactions.